Cordlife Ceases Hematopoietic Stem Cell Services

MT Newswires
02 Oct 2024

Cordlife (SGX:P8A) has decided to cease its hematopoietic stem cell (HSC) services, according to a filing with the Singapore Exchange on Tuesday.

The company said it has no plans to resume the services in the future.

However, the provider of cord blood said the decision is not going to impact its operations since HSC does not account for a significant portion of the company's revenue.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10